These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 22942237)

  • 1. Peginterferon therapy for chronic hepatitis B: one size fits all?
    Chan HL
    Gut; 2013 Feb; 62(2):185-7. PubMed ID: 22942237
    [No Abstract]   [Full Text] [Related]  

  • 2. Focus.
    Shouval D
    J Hepatol; 2013 Dec; 59(6):1151-2. PubMed ID: 24021425
    [No Abstract]   [Full Text] [Related]  

  • 3. Treatment of HBeAg-positive hepatitis B with peginterferon and lamivudine.
    Song K; Rajvanshi P
    N Engl J Med; 2005 Oct; 353(15):1630-1; author reply 1630-1. PubMed ID: 16221792
    [No Abstract]   [Full Text] [Related]  

  • 4. Peginterferon and lamivudine for hepatitis B.
    Assy NN; Hussein O
    N Engl J Med; 2004 Dec; 351(27):2879; author reply 2879. PubMed ID: 15625344
    [No Abstract]   [Full Text] [Related]  

  • 5. Peginterferon for chronic hepatitis B: predicting success with on-treatment benchmarks.
    Moucari R
    J Gastroenterol Hepatol; 2010 Sep; 25(9):1474-5. PubMed ID: 20796141
    [No Abstract]   [Full Text] [Related]  

  • 6. Treatment of HBeAg-positive hepatitis B with peginterferon and lamivudine.
    Orlent H
    N Engl J Med; 2005 Oct; 353(15):1630-1; author reply 1630-1. PubMed ID: 16224825
    [No Abstract]   [Full Text] [Related]  

  • 7. [Interferon therapy for chronic hepatitis B].
    Tang WL; Xie Q
    Zhonghua Gan Zang Bing Za Zhi; 2009 Oct; 17(10):726-9. PubMed ID: 19874685
    [No Abstract]   [Full Text] [Related]  

  • 8. To genotype or not to genotype: toward an optimal tailoring of treatment of chronic hepatitis B.
    Lin CL; Kao JH
    Clin Infect Dis; 2007 Jun; 44(12):1665-6. PubMed ID: 17516416
    [No Abstract]   [Full Text] [Related]  

  • 9. Does the addition of lamivudine to peginterferon alpha-2a sustain response rates in HBeAg-negative hepatitis B?
    Cooksley G
    Nat Clin Pract Gastroenterol Hepatol; 2005 Jan; 2(1):12-3. PubMed ID: 16265091
    [No Abstract]   [Full Text] [Related]  

  • 10. Hepatitis B e antigen as a predictor for hepatitis B e antigen-positive chronic hepatitis B patients with peginterferon alfa-2a therapy.
    Chen EQ; Tang H
    Hepatology; 2009 Nov; 50(5):1677; author reply 1677-9. PubMed ID: 19591130
    [No Abstract]   [Full Text] [Related]  

  • 11. Efficacy of thymosin α-1 plus peginterferon α-2a combination therapy compared with peginterferon α-2a monotherapy in HBeAg-positive chronic hepatitis B: a prospective, multicenter, randomized, open-label study.
    Kim BH; Lee YJ; Kim W; Yoon JH; Jung EU; Park SJ; Kim YJ; Lee HS
    Scand J Gastroenterol; 2012 Sep; 47(8-9):1048-55. PubMed ID: 22726105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The maze of treatments for hepatitis B.
    Lok AS
    N Engl J Med; 2005 Jun; 352(26):2743-6. PubMed ID: 15987924
    [No Abstract]   [Full Text] [Related]  

  • 13. [Clinical analysis of seroconversion of HBsAg in chronic hepatitis B patients treated with PegIFN alpha-2a].
    Yang F; Wu XF; Li XH; Wei N
    Zhonghua Gan Zang Bing Za Zhi; 2009 Dec; 17(12):950-1. PubMed ID: 20038343
    [No Abstract]   [Full Text] [Related]  

  • 14. Response to peginterferon alfa-2a (40KD) in HBeAg-negative CHB: on-treatment kinetics of HBsAg serum levels vary by HBV genotype.
    Brunetto MR; Marcellin P; Cherubini B; Yurdaydin C; Farci P; Hadziyannis SJ; Rothe V; Regep L; Bonino F
    J Hepatol; 2013 Dec; 59(6):1153-9. PubMed ID: 23872601
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.
    Lau GK; Piratvisuth T; Luo KX; Marcellin P; Thongsawat S; Cooksley G; Gane E; Fried MW; Chow WC; Paik SW; Chang WY; Berg T; Flisiak R; McCloud P; Pluck N;
    N Engl J Med; 2005 Jun; 352(26):2682-95. PubMed ID: 15987917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis B viral factors and treatment responses in chronic hepatitis B.
    Lin CL; Kao JH
    J Formos Med Assoc; 2013 Jun; 112(6):302-11. PubMed ID: 23787007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early serum hepatitis B virus large surface protein level: a stronger predictor of virological response to peginterferon alfa-2a than that to entecavir in HBeAg-positive patients with chronic hepatitis B.
    Zhu X; Gong Q; Yu D; Zhang D; Gu L; Han Y; Chen J; Zhang Y; Zhang X
    J Clin Virol; 2013 Aug; 57(4):318-22. PubMed ID: 23639294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B.
    Fried MW; Piratvisuth T; Lau GK; Marcellin P; Chow WC; Cooksley G; Luo KX; Paik SW; Liaw YF; Button P; Popescu M
    Hepatology; 2008 Feb; 47(2):428-34. PubMed ID: 18220290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of hepatitis B with interferon and combination therapy.
    Cooksley WG
    Clin Liver Dis; 2004 May; 8(2):353-70. PubMed ID: 15481344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantification of serum hepatitis B surface antigen: is it useful for the management of chronic hepatitis B?
    Janssen HL; Sonneveld MJ; Brunetto MR
    Gut; 2012 May; 61(5):641-5. PubMed ID: 22180061
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.